StockNews.AI
EVO
StockNews.AI
209 days

Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

1. Evotec receives $4.5m grant for developing therapies for asthma and IPF. 2. Collaboration with Yonsei University and Zymedi enhances Evotec's drug development portfolio.

2m saved
Insight
Article

FAQ

Why Bullish?

The grant indicates strong backing for innovative projects. Past grants have led to stock uplifts.

How important is it?

The grant signifies potential for future revenues and enhances market position.

Why Long Term?

Funding supports research that may yield future products. Similar collaborations historically create sustained stock value.

Related Companies

ZYMYONSEI
Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy Funding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF).

Related News